West H, et al. - Researchers compared atezolizumab plus chemotherapy vs chemotherapy alone in terms of effectiveness and safety as first-line treatment for non-squamous non-small-cell lung cancer in a multicenter, randomized, open-label, phase 3 study (IMpower130). The investigation was conducted in 131 centers across eight countries (the US, Canada, Belgium, France, Germany, Italy, Spain, and Israel). They found that patients with stage IV non-squamous non-small-cell lung cancer and no ALK or EGFR mutations had an improvement in overall survival, which was significant and clinically meaningful, as well as a significant improvement in progression-free survival with atezolizumab plus chemotherapy vs chemotherapy as first-line therapy, with no new safety signals. Overall, atezolizumab, in combination with platinum-based chemotherapy, is beneficial when given as first-line treatment for metastatic non-small-cell lung cancer.